The Park Sleep subtype in Parkinson’s disease: from concept to clinic
Authors:
Open Access
- 10 August 2023
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 24 (15) , 1725-1736
Abstract
The heterogeneity of Parkinson's disease (PD) is evident from descriptions of non-motor (NMS) subtypes and Park Sleep, originally identified by Sauerbier et al. 2016, is one such clinical subtype associated with the predominant clinical presentation of sleep dysfunctions including excessive daytime sleepiness (EDS), along with insomnia. A literature search was conducted using the PubMed, Medline, Embase, and Web of Science databases, accessed between 1 February 2023 and 28 March 2023. In this review, we describe the clinical subtype of Park Sleep and related 'tests' ranging from polysomnography to investigational neuromelanin MRI brain scans and some tissue-based biological markers. Cholinergic, noradrenergic, and serotonergic systems are dominantly affected in PD. Park Sleep subtype is hypothesized to be associated primarily with serotonergic deficit, clinically manifesting as somnolence and narcoleptic events (sleep attacks), with or without rapid eye movement behavior disorder (RBD). In clinic, Park Sleep recognition may drive lifestyle changes (e.g. driving) along with therapy adjustments as Park Sleep patients may be sensitive to dopamine D3 active agonists, such as ropinirole and pramipexole. Specific dashboard scores based personalized management options need to be implemented and include pharmacological, non-pharmacological, and lifestyle linked advice.Keywords
This publication has 143 references indexed in Scilit:
- The Heterogeneity of Early Parkinson’s Disease: A Cluster Analysis on Newly Diagnosed Untreated PatientsPLOS ONE, 2013
- Feasibility of Clinical Hypnosis For The Treatment of Parkinson's Disease:A Case StudyInternational Journal of Clinical and Experimental Hypnosis, 2013
- Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension studyThe Lancet Neurology, 2011
- Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patchBMC Neurology, 2010
- Parkinson's disease symptoms: The patient's perspectiveMovement Disorders, 2010
- REM sleep behavior disorderAnnals of the New York Academy of Sciences, 2010
- Restless legs syndrome, rapid eye movement sleep behavior disorder, and hypersomnia in patients with two parkin mutationsMovement Disorders, 2009
- Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trialJournal of Neurology, Neurosurgery & Psychiatry, 2005
- Progressive sleep ‘destructuring’ in Parkinson's disease. A polysomnographic study in 46 patientsSleep Medicine, 2005
- Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's diseaseMovement Disorders, 2002